AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02949206
Drug: 4 Factor Prothrombin Complex Concentrate (PCC)
RxNorm normalized name: Prothrombin complex concentrate
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
Trial: NCT02632305
Drug: nab-paclitaxel in combination with gemcitabine + cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
Trial: NCT00485940
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 mg o.d.
Trial: NCT00485940
Drug: Prucalopride
RxNorm normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg o.d.
Trial: NCT00411125
Drug: Oral salmon calcitonin
RxNorm normalized name: Calcitonin Salmon
DrugBank: Salmon calcitonin (DB00017)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03239483
Drug: Dapivirine gel
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine gel (0.05%); administered rectally
Trial: NCT00665444
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
Trial: NCT00101010
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m\^2 oral days 1 - 5.
Trial: NCT00101010
Drug: Vincristine Sulfate
RxNorm normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg IV, day 1
Trial: NCT01977638
Drug: CXD101
RxNorm normalized name: CXD101
DrugBank: CXD101 (DB16182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, administered orally
Trial: NCT00698451
Drug: doxorubicin HCL liposome; bevacizumab; carboplatin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
Trial: NCT01893229
Drug: Lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium is used as a mood stabiliser
Trial: NCT01893229
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate is used as a mood stabiliser
Trial: NCT01893229
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine is used as a mood stabiliser
Trial: NCT01893229
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine is used as a mood stabiliser.
Trial: NCT01893229
Drug: Ziprasidone
RxNorm normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziprasidone is used as a mood stabiliser
Trial: NCT01179672
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
Trial: NCT01447368
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
Trial: NCT03737240
Drug: Insulin Degludec (U-100)
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin Degludec (U-100) will be given once daily at the same time for 26 weeks. The dose will be titrated up to the fasting blood glucose target of 70 to 100 mg/dL, with no maximum dose.
Trial: NCT03737240
Drug: Insulin Aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the basal-bolus insulin study arm will discontinue all other diabetes medications, except for metformin which will be continued at the prescribed dose (unless contraindicated). Insulin aspart will be taken before meals with a titration schedule and dose adjustment protocol to target pre-meal blood glucose level of 70 to 100 mg/dL.
Trial: NCT00006224
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03586817
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mcg during the anesthesia
Trial: NCT03586817
Drug: Fosaprepitant
RxNorm normalized name: Fosaprepitant
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg during the anesthesia
Trial: NCT00004004
Drug: procarbazine hydrochloride
RxNorm normalized name: Procarbazine Hydrochloride
DrugBank: Procarbazine (DB01168)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01499771
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 80 Mg tablets
Trial: NCT01836367
Drug: Ingenol Mebutate 0.015%
RxNorm normalized name: INGENOL MEBUTATE 0.015% GEL,TOP
DrugBank: Ingenol mebutate (DB05013)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Picato
Trial: NCT04356495
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet daily from the first day (day 0) to day 9
Trial: NCT04356495
Drug: Ciclesonide
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 puffs twice a day in an inhalation chamber from the first day (day 0) to day 9
Trial: NCT00835770
Drug: dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BG00012 capsules
Trial: NCT00226538
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00226538
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03222323
Drug: Dexmedetomidine perineurally
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
Trial: NCT03222323
Drug: Ropivacaine 5mg/ml
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
Trial: NCT04356495
Drug: interferon β-1b
RxNorm normalized name: Interferon Beta-1B
DrugBank: Interferon beta-1b (DB00068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 10-minute nebulization, once a day, from the first day (day 0) to day 4, of 9.6 MIU / 300 µg of IFN-β-1b (EXTAVIA®) diluted in 2 mL of water
Trial: NCT03222323
Drug: Ropivacaine 7.5mg/ml
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
Trial: NCT03222323
Drug: Dexmedetomidine systemically
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
Trial: NCT03174171
Drug: Everolimus 0.75 mg
RxNorm normalized name: everolimus 0.75 MG
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus 0.75 mg b.i.d. orally for 14 days.
Trial: NCT00199966
Drug: Divalproex sodium extended release
RxNorm normalized name: divalproex sodium Extended Release Oral Tablet
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00998985
Drug: Grazoprevir
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
Trial: NCT01106599
Drug: GDC-0623
RxNorm normalized name: GDC-0623
DrugBank: GDC-0623 (DB11982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating oral dose
Trial: NCT03422029
Drug: 177Lu-Dotatate PRRT
RxNorm normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRRT using 177Lu-Dotatate 100-150mCi will be performed 8-weekly. A maximum of 8 cycles will be administered.~Other: Amino-Acid Solution The Amino-Acid Solution (AAS) to be used in this study, infused over 4-6 h, starting 30 min before PRRT
Trial: NCT03705442
Drug: loperamide (Seldiar)
DrugBank: Loperamide (DB00836)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All the patients will have access to standard drugs for diarrhoea
Trial: NCT00979472
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02280525
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.5 mg by mouth daily on Day -2 to Day +14.
Trial: NCT02280525
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
Trial: NCT02280525
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2
Trial: NCT02280525
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 2 mg/m2 by vein on Days -6 to -2.
Trial: NCT04291729
Drug: Ganovo+ritonavir+/-Interferon nebulization
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ganovo one tablet (100mg / tablet) at a time, twice a day, up to 14 days. Ritonavir one tablet(100mg / tablet) at a time, twice a day, up to 14 days.With or without spray inhalation of interferon, 50μg / time for adults, twice a day up to 14 days.
Trial: NCT00444600
Drug: Triamcinolone Acetonide + laser
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Trial: NCT00444600
Drug: Ranibizumab + laser
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
Trial: NCT00444600
Drug: Ranibizumab + deferred laser
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
Trial: NCT03802318
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole daily four time (Bid) or daily four times (Qid) Amoxicillin used daily two times (1000 mg bid) or daily four times (500 mg qid) apply in the first line or the second line H pylori eradication therapy
Trial: NCT01875744
Drug: Polyethylene glycol 4000
RxNorm normalized name: Polyethylene glycol 4000
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01254188
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
Trial: NCT02384070
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
Trial: NCT02384070
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
Trial: NCT02384070
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
Trial: NCT00477035
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg
Trial: NCT00477035
Drug: bcnu
RxNorm normalized name: BCNU
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg/kg
Trial: NCT00477035
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2
Trial: NCT00477035
Drug: vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg/m2
Trial: NCT00477035
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg/m2
Trial: NCT03674047
Drug: ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib blocks certain proteins called tyrosine kinases. Specifically, it blocks tyrosine kinases called JAK2. it's believe that ruxolitinib may lower the rate of GVHD through its ability to block the JAK2 pathway since this pathway can lead to inflammation in the body
Trial: NCT00712270
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
Trial: NCT00712270
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
Trial: NCT01288326
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
Trial: NCT02976116
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
Trial: NCT02976116
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
Trial: NCT04577612
Drug: CHI-554
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hemp-derived CBD in MCT oil
Trial: NCT03320434
Drug: Patanol
RxNorm normalized name: Patanol
DrugBank: Olopatadine (DB00768)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six drops in each eye over a 17 day period.
Trial: NCT03320434
Drug: Pred-forte
RxNorm normalized name: Pred-Forte 1% Ophthalmic Suspension
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Four drops in each eye over a 3 day period.
Trial: NCT01839981
Drug: 6,8-bis(benzylthio)octanoic acid
RxNorm normalized name: 6,8-bis(benzylthio)octanoic acid
DrugBank: Devimistat (DB12109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03202368
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
Trial: NCT02637167
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
Trial: NCT01318928
Drug: Metronidazol
RxNorm normalized name: Metronidazol
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metronidazol. 400mg x 3 per day for 10 days
Trial: NCT00005577
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00576368
Drug: INSULIN GLARGINE
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
Trial: NCT00923962
Drug: Glucagon like peptide-1
RxNorm normalized name: Glucagon like peptide-1 Elastin like peptide-120 fusion protein
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0,1 pmol/kg/min
Trial: NCT01041040
Drug: gemtuzumab
RxNorm normalized name: GEMTUZUMAB
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
Trial: NCT03099304
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT01640002
Drug: Propantheline Bromide
RxNorm normalized name: Propantheline Bromide
DrugBank: Propantheline (DB00782)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
Trial: NCT03876717
Drug: Colesevelam Hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam is a sequestrant that binds bile acids in the intestinal lumen, the bile acids are then excreted with the feces. Colesevelam is registered for treating hypercholesterolemia but it is as other sequestrants (e.g. cholestyramine and colestipol) effective against bile acid diarrhoea.
Trial: NCT01428986
Drug: Maraviroc
RxNorm normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks